HCPCS Level II code A9585 designates the administration of gadobutrol contrast, billed per 0.1 ml, primarily used to enhance magnetic resonance imaging (MRI) studies. This reagent-level code matters nationally because contrast agent billing affects imaging cost reporting, clinical documentation, and payer medical necessity reviews. Accurate coding influences facility and professional billing, inventory control, and patient cost-sharing calculations.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how A9585 is used in imaging workflows, typical sites of service where the injection is administered, and the role of per-volume contrast billing in claims and reimbursement processes. The publication reviews common modifier contexts and payer considerations where available, and it explains what benchmark and policy items are relevant to institutions that manage MRI contrast utilization.

The content is intended to help billing managers, radiology administrators, and policy analysts understand the code’s clinical context, documentation expectations, and where to look for payer-specific policy updates. Data not available in the input will be noted where applicable.